Table 4.

Suprachoroidal device characteristics

Device	Electrode specifications	Size	Advantages	SAE/AEs	Clinical Status
Gen 2 suprachoroidal device	44 active electrodes (44 × 1 μm diameter)	19 × 8 mm	- Decreased surgical complexity - Less risk of intraoperative and post operative complications - All subjects demonstrated improvement on localization tasks with device on - Expected to be suitable for at home use	No device-related SAEs	Completed clinical trial with 4 patients with RP showing to be suitable for long-term use in humans with RP
Phoenix-99	98 stimulation electrodes and one returning electrode	18.7 × 10.8 mm nominal thickness of 500 μm	Information not available	- Corneal abrasion/opacity - Corneal ulcer - Swelling - Limited blinking - Red eye - Weeping wound, discharge, light bleeding - Suture related - Dislodged orbital grommet (without erosion or VS movements) - Dislodged orbital grommet with erosion through conjunctiva and VS dislodgement - Retinal haemorrhage - Suspected retinal haemorrhage - Limited eye movements - Elevated IOP ≥ 35 mm Hg - Herniated choroid during array insertion	Completed in vivo safety study
STS	49 electrodes (500 Jim diameter and 500 Jim height)	5.8 × 5.2 × 0.5 mm	- Covers a large visual field - conforms to the curvature of the eye       - long term use	- moderate edema and hematomas observed in periorbital and head regions - Conjunctival chemosis and injection observed in all cases	Completed in vivo study of wide-field dual-array STS prosthesis